文献速递消化道肿瘤与早癌消化内镜

结直肠癌患者Lynch综合征识别策略的成本效果及对高危亲属的影响

Cost-Effectiveness of Lynch Syndrome Identification Strategies in Individuals With Colorectal Cancer and the Impact on At-Risk Relatives.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-02-24

该微模拟模型量化了结直肠癌(CRC)患者Lynch综合征(LS)筛查后对一级亲属(FDR)进行级联检测(CT)的影响。结果显示,对所有符合条件FDR行CT可使CRC病例减少61.0%、CRC死亡减少78.5%,虽终生结肠镜检查平均增加11次,但生命年和质量调整生命年小幅增加且成本降低。作者认为需进一步研究以优化CT的接受度。

要点

  • 对所有符合条件的一级亲属行级联检测,模型估计CRC病例减少61.0%、CRC死亡减少78.5%。
  • 级联检测使终生结肠镜检查平均增加11次,但生命年和质量调整生命年小幅增加。
  • 因癌症治疗费用节省,级联检测总体成本降低。

核心结论

  • 该模型量化了级联检测对新发现的结直肠癌合并Lynch综合征患者高危一级亲属的获益。
  • 跨代CRC发病率的下降可用于促进与亲属的沟通以提高级联检测的接受度。
  • 作者认为优化级联检测接受度的进一步研究对降低Lynch综合征CRC风险至关重要。

研究设计与样本

  • 研究采用微模拟模型,量化级联检测对结直肠癌患者一级亲属(父母、兄弟姐妹、子女)CRC发病率和死亡率的影响。
  • 研究对象为接受Lynch综合征筛查的结直肠癌个体的一级亲属。
  • 一级亲属的主要结局为按亲属年龄划分的CRC病例数和CRC相关死亡数;次要结局包括获得的生命年、质量调整生命年、结肠镜检查次数及级联检测、监测和癌症治疗相关成本。

主要发现

  • 对所有符合条件的一级亲属行级联检测,模型估计CRC病例减少61.0%,CRC死亡减少78.5%。
  • 级联检测导致终生结肠镜检查平均增加11次。
  • 级联检测使获得的生命年和质量调整生命年小幅增加。
  • 因癌症治疗费用节省,级联检测相关成本降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Universal screening for Lynch syndrome (LS) is recommended for all patients diagnosed with colorectal cancer (CRC). A benefit of LS screening in CRC is cascade testing (CT), whereby at-risk relatives are tested for the familial pathogenic LS variant and undergo intensive surveillance for CRC prevention/early detection if identified with LS. There is not yet universal uptake of CT; we quantify the impact on CRC-related outcomes in first-degree relatives (FDRs). METHODS: We developed a microsimulation model to quantify the impact of CT on CRC incidence and mortality in FDRs (parents, siblings, children) of individuals with CRC screened for LS. For FDRs, the primary outcome was the number of CRC cases and CRC-related deaths, by age of relative; secondary outcomes included life-years gained, quality-adjusted life-years, number of colonoscopies, and costs associated with CT, surveillance, and cancer care. RESULTS: With CT for all eligible FDRs, we estimate 61.0% decrease in CRC cases and 78.5% decrease in CRC mortality. Although CT led to an average 11 more lifetime colonoscopies, there was modest increase in life-years gained and quality-adjusted life-years and decreased costs because of savings from cancer treatment. CONCLUSIONS: This model quantifies the benefits of CT for at-risk FDRs of newly identified individuals with CRC and LS. The decrease in CRC incidence across generations can be used to facilitate discussions with relatives to improve uptake of CT. Further studies to optimize the uptake of CT are paramount to decrease risk of CRC in LS.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rustgi SD, Soddano J, Ingram M, et al. Cost-Effectiveness of Lynch Syndrome Identification Strategies in Individuals With Colorectal Cancer and the Impact on At-Risk Relatives. Clin Gastroenterol Hepatol. 2025. PMID: 40010417. doi:10.1016/j.cgh.2025.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。